Search results for ' Trastuzumab'

Cancer Therapies Break New Ground

Cancer Therapies Break New Ground

Rediff.com26 Dec 2025

'India is clearly moving toward more targeted treatment pathways in high-burden cancers.'

'Ready To Launch 5 products In 18 Months'

'Ready To Launch 5 products In 18 Months'

Rediff.com5 Jun 2025

'We recently launched Yesintek in the immunology space.'

Health budget up by 11%, daycare cancer centres announced

Health budget up by 11%, daycare cancer centres announced

Rediff.com1 Feb 2025

The Union health ministry has been allocated Rs 99,858.56 crore in the Budget 2025-2026, an around 11 per cent hike over the Rs 89,974.12 crore in the budget (revised estimates) of 2024-2025 with the government announcing setting up daycare cancer centres at all district hospitals over the next three years.

Highest Selling New Drug In India Is...

Highest Selling New Drug In India Is...

Rediff.com11 Feb 2025

Enhertu currently costs around Rs 1.6 lakh per 100-milligram injection.

'Expect formulations biz to outpace API biz'

'Expect formulations biz to outpace API biz'

Rediff.com2 Jun 2024

'API prices are dragging down margins and impacting our competitive ability.'

Budget 2024: What is cheaper, what is costlier

Budget 2024: What is cheaper, what is costlier

Rediff.com23 Jul 2024

Gold, silver and other precious metals along with imported mobile phones, certain cancer drugs and medical devices are set to become cheaper with Finance Minister Nirmala Sitharaman announcing cuts in customs duty in the Union Budget 2024-25.

'Tariffs will hurt insurance, patients and everyone'

'Tariffs will hurt insurance, patients and everyone'

Rediff.com10 Feb 2025

After registering a net profit of Rs 25.1 crore in Q3FY25 and consolidated revenues growing by 7 per cent on a like-for-like basis, Siddharth Mittal, chief executive officer (CEO) and managing director, Biocon, told Sohini Das/Business Standard in a virtual interaction that local manufacturing in the US is a trade off between cost and qualifying to do business there.

Govt cuts customs duty on 3 cancer drugs

Govt cuts customs duty on 3 cancer drugs

Rediff.com23 Jul 2024

The government proposes to cut custom duties on Trastuzumab Deruxtecan, Osimertinib and Durvalumab from 10 per cent to nil.

What Sitharaman's 7th Budget has in store for us

What Sitharaman's 7th Budget has in store for us

Rediff.com23 Jul 2024

Highlights of the Union Budget 2024-25 presented by Finance Minister Nirmala Sitharaman in Lok Sabha on Tuesday.

Biocon contests Roche claims on cancer drug

Biocon contests Roche claims on cancer drug

Rediff.com8 Feb 2014

Roche said the Indian regulatory authorities had approved Biocon and Mylan's products as Trastuzumab, but it was unclear if these met the criteria for biosimilar products.

Roche's patent pain to be Biocon's gain

Roche's patent pain to be Biocon's gain

Rediff.com19 Aug 2013

Indian firm to soon launch copycat of anti-breast-cancer drug.

Biocon Biologics Plan Molecule Launch Every 1-2 Years

Biocon Biologics Plan Molecule Launch Every 1-2 Years

Rediff.com17 Aug 2022

'The tie-up with Serum Institute Life Sciences brings to the table their strengths in manufacturing and also their vaccine portfolio.'

Drug pricing: Govt decides to bypass three patents

Drug pricing: Govt decides to bypass three patents

Rediff.com15 Jan 2013

The plan is to issue CLs for Trastuzumab (or Herceptin, used for treating breast cancer), Ixabepilone (used for chemotherapy in breast cancer treatment) and Dasatinib (or Sprycel, for leukaemia).

Is Sonali Bendre's cancer curable?

Is Sonali Bendre's cancer curable?

Rediff.com25 Jul 2018

Making healthy alterations to your diet will help starve cancer cells, suggests oncologist Dr Rakesh Bhade.